Back to top
more

Lantheus (LNTH)

(Delayed Data from NSDQ)

$97.33 USD

97.33
648,582

+0.07 (0.07%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $97.39 +0.06 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Illumina (ILMN) Sequencing Arm Grows, Margin Woes Linger

by Zacks Equity Research

Illumina's (ILMN) total sequencing activity on connected high- and mid-throughput instruments are growing strongly.

Charles River (CRL) to Aid INADcure in Plasmid DNA Manufacture

by Zacks Equity Research

Charles River (CRL) collaborates with INADcure Foundation on plasmid DNA manufacturing for developing treatments for INAD patients.

Bruker (BRKR) Launches timsTOF Ultra Mass Spec and VistaScan

by Zacks Equity Research

Bruker (BRKR) introduces the timsTOF Ultra mass spectrometer and VistaScan software for enhanced dia-PASEF 4D-Proteomics at the 71st ASMS meeting.

Quest Diagnostics' (DGX) Contract Wins Aid Amid Volume Woes

by Zacks Equity Research

Quest Diagnostics (DGX) succeeds on contract wins in its reference and professional lab services offerings.

Bruker's (BRKR) Latest Workflows to Aid Applied Markets

by Zacks Equity Research

Bruker (BRKR) introduces Novel EVOQ DART-TQ+ for chromatography-free mass spectrometry for applied markets.

Walgreens Boots (WBA) Gains From New Alliances Amid Macro Woes

by Zacks Equity Research

Continued slowdown in generic introduction has been affecting Walgreens Boots' (WBA) margins.

Is Trending Stock Lantheus Holdings, Inc. (LNTH) a Buy Now?

by Zacks Equity Research

Lantheus Holdings (LNTH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Neogen (NEOG) Introduces 2 Assays for Histamine Detection

by Zacks Equity Research

Neogen (NEOG) launches Reveal for Histamine and Reveal Q+ for Histamine assays for the detection of Histamine.

Lantheus Holdings (LNTH) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Lantheus Holdings (LNTH) possesses solid growth attributes, which could help it handily outperform the market.

LabCorp (LH) Expands Precision Oncology With Biopsy Test

by Zacks Equity Research

The addition of Labcorp Plasma Focus marks a pivotal step in the expansion of LabCorp's (LH) suite of precision oncology tests.

Illumina (ILMN) to Present Real-World CGP Data at ASCO Meet '23

by Zacks Equity Research

At the ASCO meeting, Illumina (ILMN) is set to showcase data that highlights better outcomes for cancer patients who receive comprehensive genomic testing.

Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome (Revised)

by Zacks Equity Research

Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.

Factors That Make Ensign Group (ENSG) a Lucrative Bet Now

by Zacks Equity Research

Ensign Group (ENSG) is well-poised for growth on increasing service revenues, an expanding healthcare portfolio and a strong capital position.

Myriad Genetics (MYGN) Adds New Test to Oncology Portfolio

by Zacks Equity Research

Myriad Genetics (MYGN) expands Precise Oncology Solutions portfolio by adding a new biomarker test.

Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome

by Zacks Equity Research

Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.

Exact Sciences (EXAS) Gains From New Buyouts Amid High Costs

by Zacks Equity Research

Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is now offering therapy selection tests for patients with advanced cancer.

Vaishali Doshi headshot

Add These 4 Top-Ranked Liquid Stocks to Strengthen Portfolio

by Vaishali Doshi

Here are four top-ranked liquid stocks, Chipotle Mexican Grill (CMG), Meta Platforms (META), Lantheus Holdings (LNTH) and U.S. Silica Holdings (SLCA), which investors can add to their portfolio for solid gains.

Is Lantheus Holdings (LNTH) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Lantheus Holdings (LNTH) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Is Most-Watched Stock Lantheus Holdings, Inc. (LNTH) Worth Betting on Now?

by Zacks Equity Research

Lantheus Holdings (LNTH) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Thermo Fisher (TMO) Gets FDA Clearance for Its Immunoassays

by Zacks Equity Research

Thermo Fisher (TMO) announces the FDA clearance of its blood-based biomarkers used in the determination of risk assessment and clinical management of preeclampsia with severe features.

Zacks.com featured highlights Carrols Restaurant, Celsius Holdings, VirTra, Interdigital and Lantheus

by Zacks Equity Research

Carrols Restaurant, Celsius Holdings, VirTra, Interdigital and Lantheus have been highlighted in this Screen of The Week article.

Nalak Das headshot

5 Stocks With Recent Price Strength to Maximize Your Returns

by Nalak Das

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are TAST, CELH, VTSI, IDCC, LNTH.

Illumina (ILMN) Progresses in Pathogen Genomic Technologies

by Zacks Equity Research

Illumina's (ILMN) genomic surveillance solutions enable better pathogen preparedness and response.

Hologic (HOLX) Announces Collaboration With NFL CB Kelee Ringo

by Zacks Equity Research

Hologic (HOLX) and Eagles' CB, Kelee Ringo, come together to highlight the importance of annual mammograms and other routine health screenings.

Wall Street Analysts Believe Lantheus Holdings (LNTH) Could Rally 25.73%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Lantheus Holdings (LNTH) points to a 25.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.